Authors' response by Salerno, Francesco et al.
Authors’ response
Umgelter and colleagues have reported that
there is a general reluctance to treat cirrhotic
patients with renal failure with volume
resuscitation. Moreover, they are critical of
the accuracy of diagnosing hepatorenal
syndrome (HRS) using the infusion of pre-
defined doses of albumin as recommended in
our paper.1 Finally, they do not seem to
share the opinion that HRS, once estab-
lished, is no longer responsive to simple
volume expansion, and therefore suggest
investigating a goal-directed approach of
treatment. We would like to take the
opportunity to expand our discussion on
the pathogenesis of HRS as well as on the
therapeutic resources.
The fact that volume expansion is an
essential component in the prevention and
treatment of HRS has been confirmed in
the past several years. For example, albumin
is able to prevent HRS in patients with
spontaneous bacterial peritonitis (SBP),1
and its prolonged administration is neces-
sary to improve the efficacy of terlipressin
or midodrine in reversing HRS type 1.2–4
This does not exclude, however, that
simple volume expansion is insufficient to
correct glomerular filtration rate in such
patients.
From a pathogenetic standpoint, there are
two types of functional renal failure in
cirrhotic patients: one that is caused by an
absolute loss of volume, as can occur after
over-zealous diuretic use, gastrointestinal
bleeding, diarrhoea or other dehydrating
events. In these cases, renal failure is
regarded as prerenal azotaemia, as hypovo-
laemia with reduced renal perfusion pressure
is the only cause of renal failure.5 6 This type
of renal failure is easily resolved by correc-
tion of the trigger and by volume restoration
using albumin as well as crystalloids or
colloids. The second type of renal failure is
caused by renal vasoconstriction and this is
what is defined as HRS.7 These patients
have severe effective hypovolaemia that is
not due to absolute volume loss, but rather
to a maldistribution of the total blood
volume with an excess of blood preferen-
tially located in the dilated splanchnic
vessels.8 The absolute blood volume of these
patients is not necessarily decreased and the
circulatory dysfunction is attributed to an
exaggerated stimulation of cytokines, many
of which are vasodilators, such as that
occurs with bacterial peritonitis.9 The reason
why fluid administration corrects prerenal
azotaemia but not HRS is probably due to
the fact that in prerenal failure, the intrave-
nous fluids administered are partly retained
in the central circulation, thereby improving
the total and the effective blood volume;
whereas in the latter, the intravenous fluids
are rapidly sequestered into the splanchnic
circulation, or third spaced into the peri-
toneal cavity as increased ascites, rather
than staying in the circulation to improve
the effective blood volume.10 Accordingly,
the response to blood volume expansion
in cirrhotic patients has become one of
the widely accepted criteria to separate
HRS from other forms of functional renal
failure.
Recent investigations suggest that, in
addition to peripheral vasodilation, the
already elevated cardiac output as observed
in patients with decompensated cirrhosis, is
relatively insufficient for the extent of
arterial vasodilatation and this may also
contribute to the effective hypovolaemia in
cirrhotic patients.11 The issue deserves new
accurate investigations.
HRS type 1 is a rapidly progressive form of
renal failure, and if it is not responsive to
early treatment, the patient may develop
acute tubular necrosis and die within a few
days due to multi-organ failure. This justi-
fies the indication to liver transplantation
for the patients who survive the initial insult
of renal failure.
From a practical point of view, we agree
that many previous investigations might
have used insufficient volume expansion to
diagnose HRS and that some of those
patients might have been misdiagnosed as
having HRS. This was the reason why we
decided to update the criteria of diagnosis of
HRS, replacing crystalloids with albumin,
since it seems to be the most effective colloid
in cirrhotic patients.12 In order to establish
the daily doses and total amount of albumin
to be administered, we did take into account
the importance of balancing the need to
improve the accuracy of the diagnosis of
HRS with the need to avoid any delay in
providing potentially effective treatment.
This led us to establish that a 2-day
administration was a sufficient time in most
cases, so that vasoconstrictors (or other
forthcoming therapies) are not unduly
delayed. The dose of albumin (1 g/kg b.w.)
was chosen according to the collective
experience of the experts in our panel and
also to the results of one previous trial.1 We
were concerned that a greater amount of
albumin could increase portal pressure with
the associated risk of variceal haemorrhage.13
However, table 3 of our paper states that the
infusion of albumin should be given for ‘‘at
least’’ 2 days, thereby allowing the physi-
cian to prolong the volume expansion in
individual cases for a sufficient time to
correct the intravascular volume deficit.
However, we are confident that a more
prolonged or greater infusion of albumin
could not be of benefit in treating patients
with HRS type 1, without the co-adminis-
tration of a vasoactive drug such as terli-
pressin. This opinion is supported by the
previous experience that other manoeuvres
such as the insertion of a peritoneovenous
shunt, which provided more volume expan-
sion than intravenous fluids, did not
improve renal function in patients with
HRS.14 Furthermore, a recent Spanish trial
reports that only 9% of patients with a
traditional diagnosis of HRS responded to
the administration of albumin for more than
7 days, whereas 44% of similar patients
responded to terlipressin combined with
albumin.15
With respect to the investigation of a
goal-directed circulatory treatment, we agree
with this proposal entirely, but such inves-
tigations must have predefined endpoints in
order to demonstrate the efficacy or failure
of any step of therapy. Accordingly, in our
paper, we advised that doses and frequency
of vasoconstrictors administration should be
adjusted according to blood pressure and
creatinine changes, and suggesting that
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other simple measures such as plasma sodium
and urine excretion could also be of help.
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